2017 White Paper on Recent Issues in Bioanalysis: Rise of Hybrid LBA/LCMS Immunogenicity Assays (Part 2: Hybrid LBA/LCMS Biotherapeutics, Biomarkers & Immunogenicity Assays and Regulatory Agencies’ Inputs)

Abstract

The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical companies, biotechnology companies, contract research organizations and regulatory agencies worldwide. WRIB was once again a 5-day, weeklong event – a full immersion week of bioanalysis, biomarkers and immunogenicity. As usual, it was specifically designed to facilitate sharing, reviewing, discussing and agreeing on approaches to address the most current issues of interest including both small and large molecule analysis involving LCMS, hybrid ligand binding assay (LBA)/LCMS and LBA approaches. This 2017 White Paper encompasses recommendations emerging from the extensive discussions held during the workshop, and is aimed to provide the bioanalytical community with key information and practical solutions on topics and issues addressed, in an effort to enable advances in scientific excellence, improved quality and better regulatory compliance. Due to its length, the 2017 edition of this comprehensive White Paper has been divided into three parts for editorial reasons. This publication (Part 2) covers the recommendations for biotherapeutics, biomarkers and immunogenicity assays using hybrid LBA/LCMS and regulatory agencies’ inputs. Part 1 (LCMS for small molecules, peptides and small molecule biomarkers) and Part 3 (LBA: immunogenicity, biomarkers and pharmacokinetic assays) are published in Volume 9 of Bioanalysis, issues 22 and 24 (2017), respectively.

2018 White Paper on Recent Issues in Bioanalysis: Focus on Flow Cytometry, Gene Therapy, Cut Points and Key Clarifications on Bav (Part 3 – Lba/Cell-Based Assays: Immunogenicity, Biomarkers and Pk Assays)

“…The participation of regulatory agency representatives continued to grow at WRIB [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18], covering topics and discussions in bioanalysis, biomarkers and immunogenicity:…”

Pharmacokinetic Characterization and Tissue Distribution of Fusion Protein Therapeutics by Orthogonal Bioanalytical Assays and Minimal PBPK Modeling

“…LBA and IC-LC/MS assay performance was evaluated based on fit-for-purpose approach with limited precision, accuracy and specificity as discussed previously [28]. Briefly, the LBA-based assay standard curve was fit using a 4-parameter logistic regression (4PL) algorithm with 1/y weighted regression using SoftMax Pro 7 Software (Molecular Devices, San Jose, CA).…”

ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates

“…Selection of suitable surrogate peptides from either light chain or heavy chain with good sensitivity and high specificity is critical to the quantitative accuracy and reliability of the assay. It is important to carefully evaluate both immuno-capture and proteolytic digestion efficiencies in order to develop a robust and sensitive method [95,96]. Stable isotopically labeled internal standards (SIL-IS) are usually incorporated as early in the workflow as possible to normalize as much of the process as possible for improved accuracy and precision of quantification.…”